Powered by

USAN Council Assigns Leronlimab as the Official Name for CytoDyn's PRO 140

Nov 20, 2018 - GlobeNewswire

BLA submission for first approval of leronlimab (PRO 140) on target for first quarter of 2019

Leronlimab (PRO 140) monotherapy trial results continue to impress with over 90% responder's rate

VANCOUVER, Washington, Nov. 20, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that the United States Adopted Names (USAN) Council has adopted leronlimab as the ...